Patents by Inventor Heather Sanders
Heather Sanders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981966Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.Type: GrantFiled: May 8, 2020Date of Patent: May 14, 2024Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Kevin Qu, James Prentice, Frederic Waldman
-
Patent number: 11965156Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: GrantFiled: December 7, 2021Date of Patent: April 23, 2024Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li
-
Publication number: 20230134138Abstract: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: October 31, 2022Publication date: May 4, 2023Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Publication number: 20230078942Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.Type: ApplicationFiled: September 12, 2022Publication date: March 16, 2023Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Patent number: 11486005Abstract: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.Type: GrantFiled: November 13, 2017Date of Patent: November 1, 2022Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Patent number: 11473144Abstract: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.Type: GrantFiled: November 13, 2017Date of Patent: October 18, 2022Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Patent number: 11441192Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.Type: GrantFiled: November 13, 2017Date of Patent: September 13, 2022Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Patent number: 11441188Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.Type: GrantFiled: November 13, 2017Date of Patent: September 13, 2022Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Publication number: 20220090049Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: ApplicationFiled: December 7, 2021Publication date: March 24, 2022Applicant: Quest Diagnostics Investments LLCInventors: Heather SANDERS, Hai-Rong Li
-
Publication number: 20220033901Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.Type: ApplicationFiled: August 9, 2021Publication date: February 3, 2022Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
-
Patent number: 11193120Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: GrantFiled: November 22, 2019Date of Patent: December 7, 2021Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li
-
Patent number: 11085079Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.Type: GrantFiled: October 26, 2018Date of Patent: August 10, 2021Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
-
Publication number: 20200385817Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: May 8, 2020Publication date: December 10, 2020Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Kevin QU, James PRENTICE, Frederic WALDMAN
-
Patent number: 10689710Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.Type: GrantFiled: October 28, 2015Date of Patent: June 23, 2020Assignee: Quest Diagnostics Investments IncorporatedInventors: Heather Sanders, Kevin Qu, James Prentice, Frederic Waldman
-
Publication number: 20200157527Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: ApplicationFiled: November 22, 2019Publication date: May 21, 2020Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li
-
Publication number: 20200056240Abstract: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: November 13, 2017Publication date: February 20, 2020Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Patent number: 10494629Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: GrantFiled: August 31, 2018Date of Patent: December 3, 2019Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li
-
Publication number: 20190284639Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.Type: ApplicationFiled: November 13, 2017Publication date: September 19, 2019Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Publication number: 20190112657Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.Type: ApplicationFiled: October 26, 2018Publication date: April 18, 2019Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
-
Publication number: 20190062726Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: ApplicationFiled: August 31, 2018Publication date: February 28, 2019Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li